Patents by Inventor Pravin Sudhakar Shirude

Pravin Sudhakar Shirude has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230348426
    Abstract: The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: July 8, 2021
    Publication date: November 2, 2023
    Inventors: Pravin Sudhakar Shirude, Chandrasekhar Reddy Rachamreddy, Amit Kumar Chattopadhyay, Balaji Seshadri, Vishweshwaraiah Baligar, Sudhakara Reddy Madduri, Ellen K. Kick, Nicholas R. Wurtz
  • Publication number: 20230303513
    Abstract: The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: August 11, 2021
    Publication date: September 28, 2023
    Inventors: Pravin Sudhakar Shirude, Chandrasekhar Reddy Rachamreddy, Vishweshwaraiah Baligar, Balaji Seshadri, Sudhakara Reddy Madduri, Ellen K. Kick, Nicholas R. Wurtz
  • Patent number: 11708327
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: July 25, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • Patent number: 11530183
    Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: December 20, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas R. Wurtz, Pravin Sudhakar Shirude
  • Publication number: 20220298186
    Abstract: The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: June 16, 2020
    Publication date: September 22, 2022
    Inventors: Pravin Sudhakar Shirude, Amit Kumar Chattopadhyay, Ellen K. Kick, Nicholas R. Wurtz
  • Publication number: 20210371378
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: August 12, 2021
    Publication date: December 2, 2021
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • Patent number: 11186544
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 30, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas R. Wurtz, Pravin Sudhakar Shirude, Andrew Quoc Viet
  • Patent number: 11124494
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: September 21, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pravin Sudhakar Shirude, Amit Kumar Chattopadhyay, Nicholas R. Wurtz
  • Patent number: 11117861
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: September 14, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • Publication number: 20210163443
    Abstract: Disclosed are compounds of Formula I, and pharmaceutically acceptable salts thereof: Also disclosed are pharmaceutical compositions thereof as well as methods for using the compounds in treating a variety of diseases such as, for example, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, ischemic damage, inflammatory diseases, cancers, musculoskeletal diseases, cardiovascular diseases, transplant rejection, multiple sclerosis, systemic sclerosis and neurodegenerative diseases.
    Type: Application
    Filed: December 1, 2020
    Publication date: June 3, 2021
    Inventors: Pravin Sudhakar Shirude, Satheesh Kesavan Nair, Ramesh Kumar Sistla, Ashit K. Ganguly, Ramakanth Sarabu
  • Patent number: 11008301
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pravin Sudhakar Shirude, Amit Kumar Chattopadhyay, Chandrasekhar Rachamreddy, Nicholas R. Wurtz, Ellen K. Kick
  • Publication number: 20210078971
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Application
    Filed: June 8, 2018
    Publication date: March 18, 2021
    Inventors: Pravin Sudhakar Shirude, Amit Kuma Chattopadhyay, Nicholas R. Wurtz
  • Patent number: 10787450
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: September 29, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Mandar Shrikrishna Bodas, Pravin Sudhakar Shirude, Sharanabasappa Patil, Tarun Kumar Maishal, Kamalraj Thiyagarajan, Kumaresan Chinnakotti, Peter W. Glunz
  • Publication number: 20200299237
    Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: June 11, 2020
    Publication date: September 24, 2020
    Inventors: Nicholas R. Wurtz, Pravin Sudhakar Shirude
  • Publication number: 20200255375
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: April 24, 2020
    Publication date: August 13, 2020
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • Patent number: 10717708
    Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 21, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas R. Wurtz, Pravin Sudhakar Shirude
  • Publication number: 20200207735
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Application
    Filed: June 8, 2018
    Publication date: July 2, 2020
    Inventors: Pravin Sudhakar Shirude, Amit Kumar Chattopadhyay, Chandrasekhar Rachamreddy, Nicholas R. Wurtz, Ellen K. Kick
  • Patent number: 10676431
    Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: June 9, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pravin Sudhakar Shirude, Vishweshwaraiah Baligar, Balaji Seshadri, Amit Kumar Chattopadhyay, Nicholas R. Wurtz, Ellen K. Kick
  • Publication number: 20200123108
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: June 8, 2018
    Publication date: April 23, 2020
    Inventors: Nicholas R. Wurtz, Pravin Sudhakar Shirude, Anrew Quoc Viet
  • Publication number: 20190300528
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 6, 2017
    Publication date: October 3, 2019
    Inventors: Rajeev S. Bhide, Mandar Shrikrishna Bodas, Pravin Sudhakar Shirude, Sharanabasappa Patil, Tarun Kumar Maishal, Kamalraj Thiyagarajan, Kumaresan Chinnakotti, Peter W. Glunz